Adaptimmune Therapeutics ADAP reported its Q1 earnings results on Friday, May 12, 2023 at 07:30 AM.
Here's what investors need to know about the announcement.
Earnings
Adaptimmune Therapeutics missed estimated earnings by 100.0%, reporting an EPS of $0.0 versus an estimate of $-0.14.
Revenue was up $44.03 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.07 which was followed by a 5.3% drop in the share price the next day.
Here's a look at Adaptimmune Therapeutics's past performance:
Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
---|---|---|---|---|
EPS Estimate | -0.25 | -0.24 | -0.25 | -0.22 |
EPS Actual | -0.18 | -0.24 | -0.28 | -0.32 |
Revenue Estimate | 4.12M | 4.04M | 6.00M | 3.29M |
Revenue Actual | 11.03M | 7.01M | 5.54M | 3.58M |
To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.